Penumbra REAL y-Series VR rehab system
The REAL y-Series full-body, non-tethered immersive healthcare offering for rehabilitation. [Image from Penumbra]

Penumbra (NYSE:PEN) announced today that it launched a full-body, non-tethered immersive healthcare offering for rehabilitation.

Alameda, California–based Penumbra designed its REAL y-Series product with lower and upper body sensors. They allow clinicians to track full-body movement and progress in real-time.

By expanding its virtual reality-based immersive healthcare platform, Penumbra plans to support a broad range of patients. According to a news release, these patients undergoing physical or occupational therapy could improve their physical, cognitive and mental well-being.

“Two of the largest challenges in rehabilitation are maintaining patient motivation and lack of engagement,” said Gita Barry, EVP and GM of Penumbra’s Immersive Healthcare business. “Penumbra’s latest REAL y-series is the only hands-free, sensor-based VR platform available that provides activities for both lower and upper body.”

About the Penumbra REAL-y Series

The REAL y-Series supports a wide range of conditions and levels of function, Penumbra said. As a result, it broadens utility from high-acuity to high-functioning patients. Hospitals and clinics use the system to address core and balance, cognition and functional uses. In addition, it addresses activities of daily living training and cognitive stimulation.

According to Penumbra, nearly 75% of U.S. physical therapists say patient compliance represents the biggest challenge in physical therapy today. More than half believe VR can help improve that. In addition, a majority of physical therapists (65%) expressed eagerness to use technologies like VR in their practice.

“Penumbra is advancing the latest immersive healthcare technology to help patients get back to their life with as little impairment as quickly as possible,” said Barry. “VR in healthcare can be an extraordinary resource in rehabilitation, and with our full body immersive innovation, we know we can have a tremendous impact on a broad range of patients.”